The company’s upcoming pivotal safety trial for LYN-005 is scheduled to begin in the first half of 2025. Credit: PeopleImages.com – Yuri A/Shutterstock.

Lyndra Therapeutics has announced the immediate appointment of Adam Sayer as its new president and CEO.

Sayer, who will also join the company’s board of directors, brings experience from his previous role as chief transformation officer at Envision Healthcare.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With an understanding of the healthcare ecosystem, Sayer’s expertise in strategy, transformation and payer negotiations is expected to be pivotal in progressing the company’s programmes, particularly oral weekly risperidone (LYN-005).

This long-acting therapeutic is a key focus for the company as it strives to enhance patient experience by offering less frequent dosing.

The pivotal safety trial for LYN-005 is scheduled to begin in the first half of 2025.

Adam stated: “I am excited to join Lyndra at this pivotal moment for the company. Lyndra’s LYNX platform technology has demonstrated remarkable potential to transform oral medicine delivery and make a meaningful impact on patient outcomes, and I look forward to leading this talented team as we bring the first-ever long-acting oral medicines to market.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the stewardship of Jessica Ballinger, outgoing CEO and president, the company completed a pivotal efficacy study for LYN-005.

Lyndra Therapeutics board executive chair and co-founder Amy Schulman stated: “We are grateful for Jess’s contributions and overall dedication to our mission. Now, under Adam’s leadership and with his focus on business execution, we are poised to achieve our goals and fundamentally change how oral medicines are delivered.”

The company recently entered a strategic partnership with Thermo Fisher Scientific, focusing on commercial manufacturing and clinical research on a global scale.

Lyndra’s LYNX drug delivery platform is tailored to deliver treatments for a week or more in one oral dose. The platform’s flexibility and potential have been showcased through clinical proof-of-concept studies across 25 active pharmaceutical ingredients and five therapeutic areas.